Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe

BACKGROUND: In December, 2020, two mRNA-based COVID-19 vaccines were authorised for use in the USA. We aimed to describe US surveillance data collected through the Vaccine Adverse Event Reporting System (VAERS), a passive system, and v-safe, a new active system, during the first 6 months of the US C...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblum, Hannah G, Gee, Julianne, Liu, Ruiling, Marquez, Paige L, Zhang, Bicheng, Strid, Penelope, Abara, Winston E, McNeil, Michael M, Myers, Tanya R, Hause, Anne M, Su, John R, Markowitz, Lauri E, Shimabukuro, Tom T, Shay, David K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901181/
https://www.ncbi.nlm.nih.gov/pubmed/35271805
http://dx.doi.org/10.1016/S1473-3099(22)00054-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901181/
https://www.ncbi.nlm.nih.gov/pubmed/35271805
http://dx.doi.org/10.1016/S1473-3099(22)00054-8

Ejemplares similares